TOP 100 MEDICAL SITES
| |||
|
| |||
| |||
|
| |||
| Weikang Bio-Tech: Business Continues to Thrive Weikang Bio-Tech Group (WKBT.OB) reported strong 2009 second quarter results after the markets closed yesterday. Once again, the company was able to post solid growth in sales and earnings per share. Revenues increased 544% to $13.20 million. Earning per share increased 225% to $0.13. Comments about future prospects were encouraging:Complete Story » seekingalpha.com |
Pa. House passes Phila. budget relief The Pennsylvania House of Representatives Friday passed a bill that would allow Philadelphia to close a $700 million budget gap by deferring pension payments and temporarily raising the sales tax in the city from 7 percent to 8 percent, according to the Pennsylvania House Democratic Caucus. feeds.bizjournals.com |
Insurers Drop Some Medicare Plans Insurers are dropping Medicare Advantage plans affecting more than 660,000 seniors in response to tougher federal requirements for the plans. online.wsj.com |
MannKind Corporation Q3 2009 Earnings Call Transcript MannKind Corporation (MNKD)Q3 2009 Earnings Call November 2, 2009 5:00 pm ETComplete Story » seekingalpha.com |
Immunogen's Busy Month, Part I Ohad Hammer submits: The month of December has always been a busy period for biotech investors, due to two important events: The annual meeting of American Society of Hematology (ASH) and the San Antonio Breast Cancer Symposium (SABCS). Every year, these events produce clinical data that can sharply move biotech stocks in both directions. This year, Immunogen (IMGN) is about to get center stage attention at both events. At ASH, the company and its partners will present phase I data for three different agents powered by Immunogen’s antibody-drug conjugate (ADC) technology. The most important of which is Sanofi-Aventis’ (SNY) SAR3419 in Non-Hodgkin lymphoma, a common form of blood cancer. Later that month at SABCS, Roche/Genentech (RHHBY.PK) is expected to present results for T-DM1, a high profile ADC for the treatment of breast cancer.Complete Story » seekingalpha.com |